- Home
- CNTB vs TIL Comparison
CNTB vs TIL Comparison
Compare CNTB & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | TIL |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 177.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTB | TIL |
|---|---|---|
| Price | $2.55 | $10.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.50 | ★ $100.67 |
| AVG Volume (30 Days) | ★ 659.9K | 72.7K |
| Earning Date | 03-31-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38,289.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $10.70 |
| 52 Week High | $3.28 | $42.79 |
Technical Indicators
Market Signals| Indicator | CNTB | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 36.08 |
| Support Level | $2.27 | $10.76 |
| Resistance Level | $2.87 | $11.51 |
| Average True Range (ATR) | 0.19 | 0.73 |
| MACD | -0.06 | 0.16 |
| Stochastic Oscillator | 33.85 | 2.71 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.